Clivunel Inc Drug Patent Portfolio

Clivunel Inc owns 1 orange book drug protected by 2 US patents Given below is the list of Clivunel Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8334265 Method of treatment of photodermatoses 11 Mar, 2029
Active
US10076555 Methods of inducing melanogenesis in a subject 11 Feb, 2025
Active


Given below is the list of recent legal activities going on the following drug patents of Clivunel Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Yr, Small Entity 10 Jun, 2024 US8334265
Patent Term Extension Certificate 25 May, 2023 US8334265
Notice of Final Determination -Eligible 17 Apr, 2023 US8334265
FDA Final Eligibility Letter 01 Aug, 2022 US8334265
Payment of Maintenance Fee, 4th Yr, Small Entity 14 Mar, 2022 US10076555
transaction for FDA Determination of Regulatory Review Period 04 Nov, 2021 US8334265
transaction for FDA Determination of Regulatory Review Period 22 Oct, 2021 US8334265
Second letter to regulating agency to determine regulatory review period 31 Mar, 2021 US8334265
Payment of Maintenance Fee, 8th Yr, Small Entity 10 Jun, 2020 US8334265
Letter from FDA or Dept of Agriculture re PTE application 26 May, 2020 US8334265
Initial letter Re: PTE Application to regulating agency 26 Feb, 2020 US8334265
Email Notification 10 Jun, 2019 US8334265
Change in Power of Attorney (May Include Associate POA) 10 Jun, 2019 US8334265
Correspondence Address Change 06 Jun, 2019 US8334265
Recordation of Patent Grant Mailed 18 Sep, 2018 US10076555


Clivunel Inc's Family Patents

Clivunel Inc drugs have patent protection in a total of 18 countries. It's US patent count contributes only to 14.6% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Clivunel Inc Drug List

Given below is the complete list of Clivunel Inc's drugs and the patents protecting them.


1. Scenesse

Scenesse is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8334265 Method of treatment of photodermatoses 11 Mar, 2029
(4 years from now)
Active
US10076555 Methods of inducing melanogenesis in a subject 11 Feb, 2025
(4 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Scenesse's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List